Most acne treatments on the market today work through one of a handful of familiar mechanisms — killing bacteria, drying out oil, or gently exfoliating clogged pores. Two treatments now moving through late-stage trials work through mechanisms nothing currently on a pharmacy shelf uses, and both just cleared Phase 3 with real numbers behind them. Neither is available yet. Here is what the trial data actually shows, and how far each one still has to go.
Two Genuinely New Mechanisms, Not Just New Brands
Most new acne products are variations on retinoids, benzoyl peroxide, or antibiotics. DMT310 (branded Xyngari) and denifanstat (ASC40) are different: they were built around mechanisms that do not exist in any approved acne treatment today. That matters less for marketing and more for a specific group of patients — people who have already tried the standard ladder of topical and oral options without success, or who cannot tolerate them.
DMT310 (Xyngari): A Once-Weekly Topical Made From Freshwater Sponge
DMT310 is a topical gel derived from freshwater sponge spicules — tiny structural particles that physically create microchannels in clogged pores, helping active ingredients penetrate and helping trapped material clear out. The formulation also carries antimicrobial and anti-inflammatory activity, including IL-17-targeted action, a pathway associated with inflammatory acne lesions.
Its pivotal Phase 3 trial, called STAR-1, enrolled 550 participants ages 9 and older with moderate to severe acne, using once-weekly application over 12 weeks. The trial met all of its primary endpoints, and researchers have described it as the first once-weekly topical to demonstrate that level of clinical benefit in a Phase 3 acne trial. The once-a-week dosing is the practical draw here — most current topical acne treatments require daily application, and inconsistent use is one of the most common reasons acne treatment fails in the real world.
Denifanstat (ASC40): An Oral Pill That Targets Sebum Production Directly
Denifanstat takes a different approach entirely. It is a first-in-class oral farnesyltransferase inhibitor, taken once daily, that works by inhibiting an enzyme involved in fatty-acid synthesis — which reduces the skin’s own oil (sebum) production at the source, rather than treating symptoms on the surface. Excess sebum production is one of the foundational drivers of acne, alongside clogged follicles, bacteria, and inflammation, so a drug that turns down oil production systemically is mechanistically distinct from anything oral acne medication currently does, short of isotretinoin.
Its Phase 3 trial was conducted in China with 480 participants with moderate to severe acne; 240 of them received a 50 mg daily dose over a double-blind 12-week period, with safety followed through 52 weeks. The trial met its primary and key secondary efficacy endpoints, including standard measures of overall clinical improvement and total lesion count reduction, with what the trial sponsor has described as a favorable safety profile relative to other systemic acne options.
How Far Either Actually Is From a Pharmacy Shelf
Meeting Phase 3 endpoints is a genuine milestone, but it is not an approval. Both compounds still need their sponsors to compile full trial datasets, submit for regulatory review, and clear that review before either reaches a prescription pad — a process that, even when it goes smoothly, typically takes well over a year from a positive Phase 3 readout. Denifanstat’s pivotal data so far comes from a trial run in China, which means U.S. regulators will still need their own review process before American patients can access it. Neither drug currently has a confirmed U.S. approval timeline.
Nothing about either trial changes what a good acne plan looks like today. If you are currently on a topical or oral regimen that is working, or working slowly, staying consistent with it remains the better bet than waiting on a treatment that is not available yet.
What This Means If You Have Already Tried the Standard Options
Both drugs were specifically studied in participants with moderate to severe acne, which is the population most likely to have already worked through topical retinoids, benzoyl peroxide, and possibly oral antibiotics without full resolution. If that describes your situation, the more useful next step today is not waiting for either of these to launch — it is a conversation with a dermatologist about escalating within currently available options, which for many people with persistent moderate-to-severe acne includes isotretinoin, hormonal therapy for those it applies to, or combination regimens that have not yet been tried together.
It is also worth watching for regulatory filing news specifically, rather than trial-readout news, as the more meaningful signal that either drug is getting close. A positive Phase 3 readout is necessary but not sufficient — sponsors still need to file for approval and have that review completed, and either step can add substantial additional time even after trial success.
Frequently Asked Questions
Will DMT310 or denifanstat replace retinoids and benzoyl peroxide?
Unlikely to replace them outright. More realistically, both are positioned as additional options — particularly useful for people who have not responded well to, or cannot tolerate, the current standard treatments.
Is denifanstat safer than isotretinoin?
Both target oil production, but they work through different mechanisms and have not been directly compared head-to-head in a published trial. Any decision between systemic acne medications belongs in a conversation with a dermatologist or prescriber, not a self-comparison of trial summaries.
When will these actually be available?
There is no confirmed timeline yet for either drug. Watch for regulatory filing news rather than trial-readout news as the more meaningful next milestone.
Do I need to change anything about my current routine because of this news?
No. Neither drug is available for purchase or prescription yet, so there is nothing to switch to. The practical takeaway is patience, not urgency.
Final Thoughts
Both DMT310 and denifanstat represent real mechanistic progress in a category that has not seen a genuinely new approach in years — but “met all primary endpoints in Phase 3” is a milestone on a long road, not a launch. If your current acne treatment plan feels like it is not working fast enough, that is worth a conversation with a dermatologist about your existing options today, not a reason to wait on something that is not on shelves yet.
For more on how current acne treatments actually work and what a realistic timeline looks like, browse the skincare guides at gemifys.com.
